Responsibility in Drug Advertising Act of 2025
Responsibility in Drug Advertising Act of 2025
Plain Language Summary
# Responsibility in Drug Advertising Act of 2025 - Summary **What the Bill Does** This bill would ban pharmaceutical companies from advertising new drugs directly to consumers (through TV, social media, websites, etc.) for the first three years after the FDA approves them. Currently, drug companies can advertise new medications to the public immediately after approval. The bill includes flexibility: the FDA could allow advertising during year three if it determines the ads would benefit public health, and could extend the ban beyond three years if a drug shows serious safety problems in real-world use. **Who It Affects** The bill primarily affects pharmaceutical companies, consumers, and patients. Drug manufacturers would have restrictions on marketing new medications.
Patients and doctors would see fewer advertisements for newly approved drugs during the initial three-year period. The restrictions would apply to drugs approved starting one year before the bill becomes law. **Current Status** The bill (S 483) was introduced in the 119th Congress by Senator Angus King (I-Maine) and is currently in committee, meaning it has not yet been voted on by the full Senate. This is an early stage in the legislative process.
CRS Official Summary
Responsibility in Drug Advertising Act of 2025This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media. Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources. The prohibition applies to new drugs approved beginning one year before the bill’s enactment.
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.